Immune checkpoints are vital regulators of the immune system, ensuring it does not attack the body’s own tissues indiscriminately. While this mechanism is crucial for preventing autoimmune diseases, it can also hinder the immune system’s ability to combat cancer effectively. Tumor cells often exploit these pathways to evade immune detection, particularly by targeting T cells specific to tumor antigens.
Blocking these immune checkpoints is a promising approach to reactivating antitumor immunity. By using the right antibodies, researchers can successfully block immune checkpoint proteins, allowing the immune system to resume its antitumor activity. This strategy is among the most promising for activating therapeutic anti-tumor immunity.
Bio X Cell offers a comprehensive selection of immune checkpoint blocking antibodies, including anti-PD-1, anti-CTLA-4, and anti-PD-L1. These antibodies are highly pure, with extremely low endotoxin levels and no preservatives or stabilizers, making them ideal for sensitive in vivo experiments.
For researchers looking to block specific ligand-receptor interactions that initiate immune checkpoint pathways, Bio X Cell provides reliable and effective solutions to advance cancer research.
Selected immune checkpoint antibodies from Bio X Cell in our Webshop
Direct contact technical support
Find products for your research
